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Abstract
Background: Aberrant CD40 ligand (CD154) expression occurs on both T cells and B cells in human lupus patients, which is
suggested to enhance B cell CD40 signaling and play a role in disease pathogenesis. Transgenic mice expressing CD154 by
their B cells (CD154
TG) have an expanded spleen B cell pool and produce autoantibodies (autoAbs). CD22 deficient (CD22
2/2)
mice also produce autoAbs, and importantly, their B cells are hyper-proliferative following CD40 stimulation ex vivo.
Combining these 2 genetic alterations in CD154
TGCD22
2/2 mice was thereby predicted to intensify CD40 signaling and
autoimmune disease due to autoreactive B cell expansion and/or activation.
Methodology/Principal Findings: CD154
TGCD22
2/2 mice were assessed for their humoral immune responses and for
changes in their endogenous lymphocyte subsets. Remarkably, CD154
TGCD22
2/2 mice were not autoimmune, but instead
generated minimal IgG responses against both self and foreign antigens. This paucity in IgG isotype switching occurred
despite an expanded spleen B cell pool, higher serum IgM levels, and augmented ex vivo B cell proliferation. Impaired IgG
responses in CD154
TGCD22
2/2 mice were explained by a 16-fold expansion of functional, mature IL-10-competent
regulatory spleen B cells (B10 cells: 26.7610
666 in CD154
TGCD22
2/2 mice; 1.7610
660.4 in wild type mice, p,0.01), and an
11-fold expansion of B10 cells combined with their ex vivo-matured progenitors (B10+B10pro cells: 66610
663i n
CD154
TGCD22
2/2 mice; 6.1610
662 in wild type mice, p,0.01) that represented 39% of all spleen B cells.
Conclusions/Significance: These results demonstrate for the first time that the IL-10-producing B10 B cell subset has the
capacity to suppress IgG humoral immune responses against both foreign and self antigens. Thereby, therapeutic agents
that drive regulatory B10 cell expansion in vivo may inhibit pathogenic IgG autoAb production in humans.
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Introduction
Interactions between CD40 expressed by B cells and its ligand
CD154, expressed by antigen (Ag)-activated CD4
+ helper T cells,
promotes BCR-induced B cell proliferation and survival, which is
essential for isotype switching and germinal center (GC) formation
[1,2,3,4,5,6]. Interrupting CD40 and CD154 interactions prevents
the development of both T cell-dependent (TD) humoral immune
responses and cell-mediated immune responses [7]. Agonistic
CD40 mAbs are also potent immune adjuvants for both short-
lived humoral-immunity to T cell-independent Ags [8,9] and
cellular immune responses to viruses and tumors [10,11,12].
However, CD40 agonists given during TD immune responses
actually ablate GC formation, induce a pattern of extrafollicular B
cell differentiation in the spleen and lymph nodes, prematurely
terminate humoral immune responses, block the generation of B
cell memory, and prevent the generation of long-lived bone
marrow plasma cells [13]. Consistent with this, ectopic CD154
expression by B cells in transgenic mice (CD154
TG) terminates
germinal center responses prematurely and leads to augmented
plasma cell production in T cell areas [14,15]. Expression of the
CD154 transgene in these mice is driven by immunoglobulin (Ig)
gene promoter and enhancer elements, resulting in B cell-specific
expression [14,15]. B cell CD154 expression has a precedent in
human disease, as it is expressed by both T cells and B cells in
systemic lupus erythematosus (SLE) patients and in a mouse model
of lupus [16,17,18], with ectopic B cell expression of CD154 in
aged hemizygous CD154
TG mice leading to intestinal inflamma-
tion [19] or SLE-like autoimmunity including anti-DNA autoAbs
and glomerulonephritis [20]. While a certain level of B cell CD40
signaling can exacerbate the development or severity of autoim-
mune disease, these studies collectively suggest that the fate of Ag-
specific B cells is dramatically altered by the extent of CD40
ligation, with heightened CD40 signaling potentially representing
a physiological means to limit the duration and intensity of
immune responses.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22464CD22 negatively regulates transmembrane signals in B cells
through association with the potent intracellular phosphatases
SHP-1 and SHIP [21,22,23,24]. B cells from CD22
2/2 mice are
markedly hyper-responsive to CD40 signals, whereby their ex vivo
stimulation with agonistic CD40 mAb induces a much greater
degree of proliferation relative to wild type (WT) B cells [25]. As
such, potent in vivo signals provided by constitutive CD40 signaling
combined with CD22 deficiency may alter the duration and
intensity of immune responses, size of the autoreactive B cell pool,
and autoAb production levels. To test this, CD22
2/2 mice
homozygous for the CD154 transgene (CD154
TGCD22
2/2) were
generated. Remarkably, the defining in vivo characteristic of
CD154
TGCD22
2/2 mice was a dramatic expansion in regulatory
B10 cells that were competent to express IL-10 [26,27], and
meager IgG production against both foreign and self Ags. Thus,
enhancing CD40 signaling limited the duration and intensity of
humoral immune responses likely by driving the expansion of B10
cells, a B cell subset that is also found in humans [28]. Inducing
such an expansion of B10 cells may be particularly therapeutic in
autoimmune syndromes such as SLE where aberrant CD154
expression contributes to inflammation and the generation of
pathogenic isotype-switched B cells.
Methods
Ethics statement
All animal studies and procedures were approved by the Duke
University Institutional Animal Care and Use Committee
(approved IACUC protocol #A008-08-01; Duke University
PHS Animal Welfare Assurance No. A3195-01).
Mice
CD22
2/2 mice, backcrossed with C57BL/6J mice (Jackson
Laboratories, Bar Harbor, ME) for $8 generations were previously
described [25]. CD154 transgenic mice [20] were crossed to
homozygosity and referred to as CD154
TG mice. Double mutant
mice were generated by interbreeding the F1 offspring of CD22
2/2
and CD154
TG mice, with CD154
TGCD22
2/2 mice maintained as
homozygous at both genetic loci by sibling matings. C57BL/6 WT
control mice were purchased from either The Jackson Laboratory
(Bar Harbor, ME) or NCI Frederick (Bethesda, MD). Bcl-xL
transgenic mice [29] were a kind of Dr. Michael Farrar (University
of Minnesota, Minneapolis, MN). Unless otherwise indicated, all
miceusedinthesestudieswerebetween 8and14weeksofage.Mice
were housed in a specific pathogen-free barrier facility.
Tissue harvest, flow cytometry and Abs
Single-cell suspensions were isolated from spleen, BM, periph-
eral LNs, and the peritoneal cavity. Spleen and BM RBCs were
depleted using ammonium chloride-Tris lysis buffer. Blood was
obtained by retroorbital puncture. Leukocytes (0.5–1610
6) were
stained at 4uC using predetermined optimal concentrations of Abs
for 30 min, then analyzed by flow cytometry. Blood RBCs were
lysed following surface staining using BD FACS
TM Lysing
Solution (BD Biosciences). Cells were analyzed on a FACSCanto
II flow cytometer (BD Biosciences). Abs against surface or
intracellular mouse proteins were as follows: B220 (RA3-6B2),
CD21/35 (7G6), CD24 (M1/69), CD25 (PC61), GL-7 (Ly-77),
CD154 (MR1), CD23 (B3B4), CD44 (IM7), CD1d (1B1), CD90.2
(53-2.1), all from BD Pharmingen; IgM (11/41), B220 (RA3-6B2),
CD21/35 (eBio8D9), CD23 (B3B4), CD93 (AA4.1), CD1d (1B1),
CD5 (53-7.3), CD62L (MEL-14), Foxp3 (FKJ-16s), IL-10 (JES5-
16E3), MHC class II (I-A
b clone MC/114), all from eBioscience
Inc. (San Diego, CA); goat anti-mouse IgM or IgD (Southern
Biotechnology Associates, Inc.) To detect intracellular IL-10, a BD
Cytofix/Cytoperm Kit was used. To detect intracellular Foxp3, a
Foxp3 Staining Buffer Set was used (eBioscience Inc.).
B cell isolation, proliferation and survival assays
Single cell splenocyte suspensions isolated under aseptic
conditions were enriched for B cells using a B Cell Isolation Kit
(Miltenyi Biotech), yielding .95% B220
+ cells. B cells (1610
6
cells/ml) were cultured in RPMI 1640 medium supplemented with
10% FCS, 10 mM HEPES, 55 mM 2-mercaptoethanol either
alone or in the presence of F(ab9)2 goat anti-mouse IgM Ab
(Cappel), or CD40 mAb (clone HM40-3, BD Pharmingen).
Proliferation was measured by incorporation of [
3H]-thymidine
(1 mCi/well) added during the final 18 h of 72 h cultures, followed
by scintillation counting. Alternatively, B cells were labeled with
1 mM CFSE before culture using a Vybrant CFDA SE Cell Tracer
Kit (Molecular Probes) and analyzed for CFSE dilution by flow
cytometry, with viable cells determined by 7-amino-actinomycin D
(7-AAD) exclusion.
Immunofluorescence microscopy
For visualization of CD1d
hi B cells in situ,5mm cryostat spleen
sections were stained with FITC-conjugated B220 mAb and PE-
conjugated CD1d mAb. Digital images were merged to identify
CD1d
hi B cells within follicles and MZ regions. To visualize GL7
+
B cells in situ, spleen sections were stained with FITC-conjugated
GL7 mAb and PE-conjugated B220 mAb. Digital images were
merged to identify GL7
+ B cells within GCs or other follicle
regions.
Experimental autoimmune encephalomyelitis (EAE)
experiments
Purified spleen B cells from CD154
TGCD22
2/2 donor mice
were surface labeled with CD1d and CD5 mAbs, with
CD1d
hiCD5
+ and CD1d
loCD5
2 B cell populations isolated using
a FACSVantage SE flow cytometer with purities of 95–98%.
1610
6 cells were either directly transferred i.v. into WT recipient
mice, or were first cultured with agonistic CD40 mAb for 48 h
with LPS added during the final 5 h of culture, then washed and
transferred. One day after cell transfers, EAE was induced in
recipient mice with clinical signs of EAE scored daily as described
[30,31].
Immunizations
In some experiments, WT, CD22
2/2, CD154
TG, and
CD154
TGCD22
2/2 mice were immunized i.p. with 100 mg
DNP-KLH in CFA, and then boosted on day 21 with DNP-
KLH in IFA. Serum Ag-specific Ig levels were determined by
ELISA. Alternatively, the mice were immunized i.p. with 50 mg4 -
hydroxy-3-nitrophenyl acetyl-conjugated chicken c-globulin
(NP8CGG) in alum, with spleens were harvested on day 10 and
the splenocytes stained with GL-7 and B220 mAbs, with double-
positive B cells identified by flow cytometry. In other experiments
where adjuvant was excluded, WT mice were immunized i.p. with
100 mg DNP-KLH in PBS alone, and then boosted on day 21 with
DNP-KLH in PBS alone.
ELISAs and ELISPOT assays
Serum IgMandIgGlevelsand serum IgM and IgGautoAblevels
were determined by ELISA. 96-well microtiter plates (Costar,
Cambridge, MA) were coated overnight at 4uC with either 5 mg/ml
goat anti-mouse Ig(H+L) Abs (BD Pharmingen), 2 mg/ml of calf
thymus double- or single-stranded DNA (Sigma-Aldrich, St. Louis,
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Aldrich). Single stranded DNA was obtained by boiling calf thymus
dsDNA in 16 SSC for 10 minutes, followed by immediate
immersion in ice. Coated plates were blocked for 1 hr at RT with
Tris-buffered saline containing 1% BSA and 2% gelatin, then
incubated for 1 hr at RT with pre-determined concentrations of
sera diluted in Tris-buffered saline containing 1% BSA. Bound Abs
were detected with alkaline phosphatase-conjugated goat anti-
mouse IgG or IgM Abs (Southern Biotechnology Associates,
Birmingham, AL). Ig levels were determined by quantifying serum
titers against known standards (purified mouse IgM or IgG,
Southern Biotechnology Associates). Alkaline phosphatase activity
was detected using p-nitrophenyl phosphate substrate (Sigma-
Aldrich) at a wavelength of 405 nm.
DNP-specific Ab levels were determined by ELISA as described
[32]. Briefly, sera from DNP-KLH-immunized mice were diluted
1:1000 for analysis using ELISA plates coated overnight at 4uC
with 100 mg/ml DNP-BSA (Calbiochem-Novabiochem Corp.).
Bound Ag-specific IgM and IgG Abs were then detected with
alkaline phosphatase-conjugated goat anti-mouse IgM or isotype-
specific IgG Abs, as above. Ab-secreting cell frequencies were
determined by ELISPOT assay as described [33]. Briefly, dilutions
of spleen B cells were cultured in DNP-BSA-coated Multiscreen
HTS IP plates (Millipore, Bedford, MA) for 5 hours. After
extensive washing, the plates were incubated with alkaline
phosphatase-conjugated goat anti-mouse IgG Ab, with the spots
counted using a dissecting microscope.
CD22 mAb treatment
The MB22-10 mAb and an isotype-matched control mAb
(250 mg/mouse) were given to mice i.v. as previously described to
deplete CD1d
hiCD5
+ B cells [34] and IL-10-competent B10 cells
[31].
Statistical analysis
All data are shown as means (6SEM), unless otherwise noted.
The Student’s t-test was used to determine the significance of
differences between sample means.
Results
B cell phenotype and numbers in CD154
TGCD22
2/2 mice
The biological effects of CD22-deficiency are B cell intrinsic as
CD22 expression is only expressed by B cells [25]. Furthermore,
transgenic CD154 was specifically expressed by B cells in
homozygous CD154
TG mice, but not on other lymphocytes or
other hematopoietic cells in the blood or spleen (Figure 1A–B, data
not shown) as previously documented for hemizygous CD154
TG
mice [20]. To examine the combined effects of B cell intrinsic
CD154 expression and CD22-deficiency, CD154
TGCD22
2/2
double mutant mice homozygous at both genetic loci were
generated by intercrossing the F1 progeny of breedings between
hemizygous CD154
TG mice [20] and CD22
2/2 mice [25].
CD22
2/2, CD154
TG, and CD154
TGCD22
2/2 mice all devel-
oped and bred normally. A subpopulation of blood B cells of both
CD154
TG (4361%, n=6) and CD154
TGCD22
2/2 (6061%,
n=6) mice expressed detectable cell surface CD154 (Figure 1A),
with intermediate CD154 expression by hemizygous mice (data
not shown). Cell surface CD154 expression was much lower on
spleen B cells, as previously reported for hemizygous CD154
TG
mice [20], indicating CD154 internalization subsequent to CD40–
CD154 engagement within the spleen.
CD154
TGCD22
2/2 spleen B cells exhibited the chronically-
activated phenotype typical of CD22
2/2 B cells [25], with
increased CD5 expression (Figure 1C), as well as enhanced MHC
class II and decreased cell surface IgM expression (data not
shown). Spleen B220
+IgM
+ B cell numbers were increased by 2.5-
fold in CD154
TGCD22
2/2 mice relative to WT mice, while a 3.6-
fold increase was observed in CD154
TG mice (Table 1). Spleen
Thy1.2
+ T cell and Foxp3
+CD25
+CD4
+ regulatory T cell (Treg)
numbers did not differ significantly between WT, CD22
2/2,
CD154
TG, and CD154
TGCD22
2/2 mice. However, memory
CD4
+ and CD8
+ T cell numbers were significantly increased in
CD154
TGCD22
2/2 and CD154
TG mice. Thus, the predominant
effect of ectopic CD154 expression was the significant expansion of
spleen B cells in CD22
2/2 mice, coupled with expanded memory
T cell populations.
The CD1d
hiB220
+ marginal zone (MZ) B cell population was
significantly reduced in CD22
2/2 mice as assessed in frozen
spleen sections (Figure 1D), as published [24,34,35]. Remarkably,
the MZ B cell population was restored in CD154
TGCD22
2/2
mice, revealing that CD40 ligation overcomes the effects of CD22
deficiency on MZ maintenance. Nevertheless, CD1d
hiB220
+ cells
were also observed within B cell follicles of all genotypes. CD1d
hi
B cells were particularly abundant within the MZ and follicles of
CD154
TGCD22
2/2 mice (highlighted in the enlarged region),
paralleling their overall high numbers relative to the other mouse
lines (Figure 1E).
CD22
2/2 B cells proliferate much more extensively than WT B
cells when cultured with agonistic CD40 mAb [25]. B cells from
CD154
TG mice proliferated less than WT B cells following CD40
stimulation as quantified by [
3H]-thymidine incorporation
(Figure 1F), suggesting desensitization of the CD40 pathway in
these mice. However, CD154
TGCD22
2/2 B cells proliferated more
extensively than WT B cells following CD40 stimulation, indicating
that the hyper-responsiveness caused by CD22 deficiency persists in
these cells. Altered CD40 expression does not explain these results,
as cell surface CD40 expression was equivalent on spleen B cells
from WT, CD22
2/2, CD154
TG and CD154
TGCD22
2/2 mice as
determined by immunofluorescence staining with flow cytometry
analysis (data not shown). Similar to CD40 ligation, proliferation of
CD154
TGCD22
2/2 and CD22
2/2 B cells in response to LPS
stimulation was modestly enhanced relative to WT or CD154
TG B
cells as quantified by CFSE dilution analysis (Figure 1G).
In contrast to CD40 stimulation, CD22
2/2 B cells undergo
apoptosis following extensive BCR ligation due to blocked cell cycle
progression [25]. Likewise, proliferation of B cells from
CD154
TGCD22
2/2 mice was profoundly deficient following BCR
ligation with F(ab)92 anti-IgM Ab and nearly identical to the defect of
CD22
2/2 B cells (Figure 1F). Without CD40 or BCR stimulation,
background levels of B cell [
3H]-thymidine incorporation were low, but
were significantly higher (P,0.01) for B cells from CD154
TGCD22
2/2
and CD154
TG mice than for WT and CD22
2/2 mice (data not
shown). Consistent with this, purified B cells from both CD154
TG and
CD154
TGCD22
2/2 mice remained viable when cultured for .10
days without any exogenous mitogenic stimulation, while
CD154
TGCD22
2/2 B cells uniquely proliferated at significant levels
as assessed by CFSE dilution (Figure 1H). Collectively, these data
demonstrate that B cells in CD154
TGCD22
2/2 mice are capable of
receiving CD40 and additional costimulatory signals that promote B
cell activation, survival, and proliferation.
Importantly, transgenic CD154 engagement of CD40 in
CD154
TG and CD154
TGCD22
2/2 mice appears to be primarily
mediated through cis (same cell) interactions on B cells, since
mixed bone marrow chimeras derived from WT and CD154
TG
donors exhibit enhanced Ab production specifically from
CD154
TG B cells [14,15]. Also, activation markers on dendritic
cells are not altered in CD154
TG mice relative to WT mice
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with agonistic CD40 mAb, CFSE-labeled CD22
2/2 spleen B cells
co-cultured with CD154
TGCD22
2/2 spleen B cells ex vivo did not
exhibit enhanced survival or proliferation compared to CD22
2/2
B cells cultured alone (data not shown). These observations
strongly suggest that the phenotypic alterations observed in
CD154
TG and CD154
TGCD22
2/2 mice are mediated by
enhanced, autocrine CD40 signaling in the B cell lineage, and
not through the activation of bystander cells in other lineages that
also express CD40.
Table 1. Lymphocyte subsets in WT, CD22
2/2, CD154
TG, and CD154
TGCD22
2/2 mice
a.
Lymphocyte number (610
26)
Tissue Phenotype WT CD22
2/2 CD154
TG CD154
TGCD22
2/2
BM: B220
hiIgM
hi 1.560.3 0.460.2* 1.260.3 0.560.03*
B220
hiHSA
lo 1.460.2 0.360.1** 1.460.3 0.360.04**
Blood: B220
+ 2.7610 . 9 60.2* 3.9610 . 4 60.1**
Spleen: B220
+IgM
+ 68694 6 682 5 0 640** 171620**
B10
b 1.760.4 1.860.4 6.562** 26.766**
B10+B10pro 6.1625 . 4 60.8 2464** 6663**
IgM
+IgD
+CD23
hi 56684 2 672 2 4 650* 127620*
IgM
hiCD21
hi 5.660.9 1.460.3** 2464** 2966*
CD1d
hiCD5
+ 1.860.4 2.360.8 4.260.3** 3165*
B220
loCD5
+ 2.260.5 1.760.4 9.263* 6.661*
Thy1.2
+ 39653 8 673 9 645 3 69
CD4
+Foxp3
+CD25
+ 3.460.2 3.360.4 2.760.4 4.460.8
CD4
+ Tn a ı ¨ve 15641 8 651 1 628 . 5 64
CD4
+ T memory 6.960.8 5.860.8 9.760.6* 1463*
CD8
+ Tn a ı ¨ve 13621 4 635 . 9 61* 2.060.6**
CD8
+ T memory 0.760.08 0.860.1 9.161** 1563**
IL-10
+ Tc e l l s
c 0.660.2 0.860.2 6.462.5* 8.162.2**
PLN: B220
+ 4.660.8 1.960.2* 9.461* 4.462
B10 0.0160.005 0.00360.001 0.0660.01* 0.260.1*
MLN: B10 0.0260.01 0.0260.003 0.360.06** 0.460.2*
PC: B220
+IgM
+ 0.760.1 0.360.1 2.960.6* 1.260.3
B10 0.660.1 0.560.1 0.760.1 0.760.3
B220
loCD5
+ 0.460.1 0.360.1 1.060.3 0.460.1
B220
hiIgD
hi 0.560.1 0.260.1 2.460.5* 1.060.2
aNumbers represent mean (6SEM) values from $4 littermates of each genotype. Asterisks indicate values significantly different from WT mice (*p,0.05; **p,0.01). PLN,
peripheral LN; MLN, mesenteric LN; PC, peritoneal cavity.
bB10 and B10pro cells were identified as in Figure 3.
cIL-10-competent T cells were identified following 5 h stimulation with PMA/ionomycin.
doi:10.1371/journal.pone.0022464.t001
Figure 1. B cell development in CD154
TGCD22
2/2 and CD154
TG mice. (A) B cell CD154 expression in WT, CD22
2/2, CD154
TG and
CD154
TGCD22
2/2 mice. Blood and spleen B220
+ B cells were assessed for CD154 expression by immunofluorescence staining with flow cytometry
analysis. Dashed lines delineate borders between CD154
+ and CD154
2 cells as determined using WT lymphocytes. (B) Ectopic CD154 expression is B
cell-restricted in CD154
TGCD22
2/2 mice. CD154 expression by blood and spleen B220
+ and B220
2 mononuclear cells was assessed by
immunofluorescence staining with flow cytometry analysis. Results represent those obtained in 6 pairs of mice. (C) Increased CD5 expression by B
cells from CD22
2/2 and CD154
TGCD22
2/2 mice. Spleen B cells were assessed for CD5 expression by immunofluorescence staining. Gates indicate
percentages of CD5
+ B cells among total B220
+ cells. (D) Spleen CD1d
hiB220
+ B cell localization. Tissue sections from WT, CD22
2/2, CD154
TG, and
CD154
TGCD22
2/2 mice were stained with B220 (FITC, green) and CD1d (PE, red) mAbs. Merged images highlight CD1d
hiB220
+ cells (yellow). (A–C)
Results are representative of $3 mice of each genotype. (E) Spleen CD1d
hiB220
+ B cell numbers in WT, CD22
2/2, CD154
TG and CD154
TGCD22
2/2
mice as determined by immunofluorescence staining. Results represent the mean (6SEM) from $3 mice of each genotype. (F) CD154
TGCD22
2/2 B
cells are hyper-responsive to CD40 signals. Spleen B cells from WT, CD22
2/2, CD154
TG, and CD154
TGCD22
2/2 mice were cultured with mitogenic
CD40 mAb or anti-IgM Ab for 72 h, with [
3H]-thymidine incorporation assessed during the final 18 h of culture. Values represent means (6SEM) of
triplicate cultures. (E–F) Means significantly different from WT values are indicated by asterisks (**p,0.01), and between other genotypes by crosses
({{p,0.01). (G) CD154
TGCD22
2/2 B cell proliferation in response to LPS stimulation. Cell division of CFSE-labeled B cells from WT, CD22
2/2, CD154
TG
and CD154
TGCD22
2/2 mice following LPS stimulation was quantified after 72 h in culture by flow cytometry. (F–G) Results are representative of 2
independent experiments with similar results. (H) Enhanced survival by CFSE-labeled B cells from CD154
TG and CD154
TGCD22
2/2 mice after 10 days
in culture without mitogenic stimulation as assessed by flow cytometry. Results represent 3 independent experiments producing similar results.
doi:10.1371/journal.pone.0022464.g001
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CD154
TGCD22
2/2 mice
Serum IgM concentrations were significantly higher in both
CD22
2/2 (155% increase) and CD154
TG (125% increase) mice at
4 mos of age when compared with WT mice, but were dramatically
higher (1,220% increase) in CD154
TGCD22
2/2 mice (Figure 2A).
At 12 mos of age, IgM levels were equally high in both
CD154
TGCD22
2/2 and CD22
2/2 mice. By contrast, serum IgG
levels were reduced in both CD154
TGCD22
2/2 and CD22
2/2
mice at 4 mos of age, and remained significantly reduced in 12 mo-
old CD154
TGCD22
2/2 mice relative to all other genotypes. Thus,
IgM levels were high in CD154
TGCD22
2/2 mice during early life,
with little IgG Ab produced throughout life.
IgM autoAbs reactive with dsDNA, ssDNA and histone protein
were significantly higher in both CD154
TGCD22
2/2 and
CD22
2/2 mice at 12 mos of age, while CD154
TG mice only
had significant levels of IgM autoAbs reactive with dsDNA
(Figure 2B). CD22
2/2 mice also generated significant levels of IgG
autoAbs reactive with dsDNA and ssDNA, but IgG autoAbs were
virtually absent in CD154
TGCD22
2/2 mice. Therefore,
CD154
TGCD22
2/2 mice produced IgM but not IgG autoAbs.
Following immunization with the TD Ag DNP-KLH in
Freund’s adjuvant, WT, CD22
2/2, and CD154
TG mice generated
significantly stronger DNP-specific IgG responses than
CD154
TGCD22
2/2 mice (Figure 2C). Remarkably, classical GC
structures were absent in the spleens of both CD154
TG and
CD154
TGCD22
2/2 mice after the boost phase of DNP-KLH
immunization as assessed by in situ immunofluorescence staining of
frozen spleen sections (Figure 2C). Nevertheless, relatively rare
GL7
+B220
+ B cells were detectable within the B cell follicles of
spleens from CD154
TG mice, but not within the spleens of
CD154
TGCD22
2/2 mice (Figure 2C, enlarged regions). Despite
lacking classical GCs, the presence of detectable GL7
+B220
+ B
cells in CD154
TG spleens (Figure 2C–D) coupled with their 4-fold
spleen B cell expansion (Table 1) suggests that enough ‘‘GC-like’’
B cells are present to produce significant isotype switched IgG
antibody. Similar results were obtained from mice immunized
using the TD Ag NP8-CGG in alum, followed by quantitative
analysis of total spleen GL7
+B220
+ B cells by flow cytometry. The
frequency of spleen GL7
+ B cells was significantly reduced in both
CD154
TGCD22
2/2 (90% reduced) and CD154
TG (77% reduced)
mice relative to WT mice after immunization (Figure 2D, contour
plots). However, the total number of GL7
+ B cells induced
following immunization was specifically reduced in
CD154
TGCD22
2/2 mice (62%, bar graphs), remaining normal
in CD154
TG mice as a result of their expanded B cell pool. Thus,
global IgG immune responses were specifically impaired in
CD154
TGCD22
2/2 mice.
B10 cells expand dramatically in CD154
TGCD22
2/2 mice
Lending importance to the observed expansion of CD1d
hi B
cells in CD154
TGCD22
2/2 mice (Figure 1D–E), a novel subset of
regulatory IL-10-producing B cells termed ‘B10’ cells was recently
identified within the spleen CD1d
hiCD5
+ subpopulation
[27,30,36,37]. Through in vivo adoptive transfer and depletion
experiments, B10 cells were found to suppress autoimmunity and
inflammation in mouse models of disease [30,37,38]. Remarkably,
B10 cell frequencies and numbers were increased dramatically
within the spleens of CD154
TGCD22
2/2 mice, with 16-, 15-, and
4.1-fold higher B10 cell numbers than in WT, CD22
2/2,o r
CD154
TG mice, respectively (Figure 3A and Table 1). B10 cell
numbers in tissues other than spleen were modest in all four
genotypes (Figure 3A). B10 cells from WT, CD22
2/2, CD154
TG,
and CD154
TGCD22
2/2 mice expressed similar phenotypes with
augmented levels of CD19, IgM, CD21 and CD24, as well as low
to intermediate levels of CD23 and IgD (Figure 3A–B). Despite
their dramatic increase in spleen B10 cell numbers, serum IL-10
levels were not measurable in 4 mo-old CD154
TGCD22
2/2 mice
(n=9, data not shown). Enhanced in vivo survival signals alone
were unlikely to explain B10 cell expansion, since spleen B10 cell
frequencies and numbers were normal in 10 week-old Bcl-xL
transgenic mice (2.460.9%, 9.260.9610
5, n=6) relative to their
WT littermates (2.660.2%, 7.461.4610
5, n=3). Therefore, B10
cells were remarkably expanded in CD154
TGCD22
2/2 mice,
while retaining a phenotype similar to WT B10 cells.
A fraction of spleen CD1d
hiCD5
+ B cells, called B10 progenitor
(B10pro) cells, is induced to become IL-10 competent during 48 h
cultures with agonistic CD40 mAb [27]. Since it is not yet possible
to phenotypically distinguish existing B10 cells from in vitro
matured B10pro cells, IL-10-producing B cells under these
conditions are collectively defined as ‘B10+B10pro’ cells. Spleen
B10+B10pro cell numbers in CD154
TGCD22
2/2 mice were 11-,
12-, and 2.8-fold higher than in WT, CD22
2/2, and CD154
TG
mice, respectively (Figure 3C and Table 1).
B10 cells in CD154
TGCD22
2/2 mice are regulatory
Spleen B10 cells localize primarily within the CD1d
hiCD5
+
subpopulation in WT mice (Figure 4A) as described [37]. Likewise,
spleen B10 cells in CD154
TGCD22
2/2 mice were found primarily
within the CD1d
hiCD5
+ population (Figure 4A), where they
represented .50% of the cells (bar graphs). This was .3 times the
15% frequency of B10 cells found within the CD1d
hiCD5
+
population of WT mice, and far above the 4% frequency of B10
cells found within the CD1d
loCD5
2 subpopulation of
CD154
TGCD22
2/2 mice.
The adoptive transfer of B10 cells from WT mice into syngeneic
recipient mice significantly reduces the severity of EAE, an
acutely-induced model of multiple sclerosis [30]. Whether B10
cells in CD154
TGCD22
2/2 mice were capable of influencing EAE
was therefore assessed. Spleen CD1d
hiCD5
+ (B10-rich) B cells and
CD1d
loCD5
2 (B10-poor) B cells were purified from naive
CD154
TGCD22
2/2 mice (Figure 4B) and adoptively transferred
into WT mice 24 h before myelin oligodendrocyte glycoprotein
(MOG) immunization to induce EAE. Unmanipulated
CD1d
hiCD5
+ B cells from CD154
TGCD22
2/2 mice significantly
reduced EAE severity (cumulative EAE score, 2864, p,0.05),
while disease was not altered in mice given CD1d
loCD5
2 B cells
(3863) relative to mice given PBS as a control (4065; Figure 4C,
upper panel).
The frequency of IL-10-competent B10 cells among
CD1d
hiCD5
+ B cells is enhanced by B10pro cell maturation in
vitro (Figure 3) as described [27]. Therefore, CD1d
hiCD5
+ and
CD1d
loCD5
2 B cells purified from CD154
TGCD22
2/2 mice
were stimulated with agonistic CD40 mAb for 48 h, with LPS
added during the final 5 h of culture. The adoptive transfer of
CD40/LPS-stimulated CD1d
hiCD5
+ B cells dramatically inhibit-
ed EAE progression (cumulative EAE score, 1765, p,0.01), while
CD1d
loCD5
2 B cells did not (3866; Figure 4C, lower panel). As
such, B10 cells from CD154
TGCD22
2/2 mice had a regulatory
capacity when transferred into WT mice.
B10 cell depletion in vivo enhances IgG production in WT
mice
A mAb that engages the ligand binding domains of CD22
(MB22-10 mAb) preferentially depletes spleen B10 cells and B cells
with a CD1d
hi phenotype in WT mice [31,34]. Likewise, depletion
of the CD1d
hiCD5
+ spleen B cell population that harbors most
B10 cells was dramatic (.70%) in WT mice 7 days following a
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Spleen B10 cell frequencies and numbers were also reduced
.60% in MB22-10 mAb-treated mice relative to control mAb
treated mice (Figure 5B). Follicular CD1d
loCD5
2 and other
CD19
+ non-B10 B cell frequencies and numbers were not
significantly affected by MB22-10 mAb treatment (Figure 5A–B,
and data not shown). Thus, CD22 mAb treatment efficiently
depleted spleen B10 cells while leaving most other spleen B cells
intact.
Effective B10 cell depletion by MB22-10 mAb in WT mice
provides a system to verify that the expansion of B10 cells in
CD154
TGCD22
2/2 mice contributes to their modest IgG
responses. Since CD154
TGCD22
2/2 mice do not express CD22
and are thus not amenable to the use of CD22 mAb, it was
determined whether B10 cell depletion by MB22-10 mAb would
enhance IgG responses in WT mice immunized with a TD Ag in
the absence of adjuvant. DNP-KLH immunization induced
significant primary and secondary (day 21 boost) DNP-specific
IgM responses in control mAb-treated WT mice, while DNP-
specific IgG responses rose only slightly above background levels
(Figure 5C). By contrast, MB22-10 mAb-treated mice generated
normal Ag-specific IgM responses and robust DNP-specific IgG1,
IgG2c, IgG2b, and IgG3 Ab responses that remained high. MB22-
10 mAb treatment also significantly expanded the frequency of
spleen IgG-secreting B cells in comparison with control mAb-
treated mice (Figure 5D). Thereby, B10 cell depletion dramatically
enhanced IgG immune responses in WT mice.
Discussion
CD154 is expressed at relatively high levels by both T cells and
B cells in SLE patients and in a mouse model of lupus, which is
proposed to drive CD40 signaling, B cell hyperactivity, and
autoAb production [16,17,18]. Although CD154 expression by B
cells in the current study appears lower by comparison, the
combination of CD154 expression and CD22 deficiency signifi-
cantly enhanced B cell responses to CD40 signaling (Figure 1). B
cell CD154 expression in CD154
TGCD22
2/2 mice also led to a
remarkable 16-fold expansion of the regulatory B10 cell subset
relative to WT mice. B10 cells normally represent only 1–3% of
spleen B cells in WT mice [30,37]. In fact, B10 cells alone
represented 16% of spleen B cells in CD154
TGCD22
2/2 mice,
while B10+B10pro cells represented 39% of spleen B cells. B10 cell
expansion also paralleled a dramatic reduction in B cell isotype
switching, with lower IgG Ab and autoAb levels in
CD154
TGCD22
2/2 mice than were present in the parental
mouse lines, even after immunization using a strong TD Ag in
adjuvant. IgG deficiency was not observed in CD154
TG mice
where spleen B10 cells were only expanded 3.8-fold and total
spleen B cells were expanded 3.6-fold (Figure 3A and Table 1).
Thus, heightened CD40 signaling through the combination of
chronic CD154 expression and CD22-deficiency drove the in vivo
expansion of regulatory B10 cells with functional activity, and
limited the intensity of IgG immune responses, both of which may
limit the pathogenic consequences of autoimmunity.
B cell negative regulation of immune responses through the
production of IL-10 has been demonstrated in EAE [30,39,40,41]
and other mouse models of autoimmunity and inflammation
[30,36,42,43,44,45]. These B cells are called ‘‘B10 cells’’ because
IL-10 secretion is required for their negative regulatory function,
and other B cell subsets with their own unique regulatory
properties may also exist [26]. B10 cells have a potent capacity
to down-modulate immune responses during adoptive transfer
experiments [30,37,38,46], a property clearly retained by
CD154
TGCD22
2/2 B10 cells (Figure 4C). Spleen B10 cells are
predominantly contained within the phenotypically unique
CD1d
hiCD5
+ subpopulation and are presumed to be functionally
mature since they are competent to express quantifiable IL-10
after 5 h of ex vivo stimulation [30,37]. B cell regulatory functions
are also enhanced by ex vivo CD40 or LPS stimulation in
inflammation and autoimmunity models [40,47,48,49], although
CD40 or TLR signaling are not required for B10pro or B10 cell
generation [27]. However, CD40 signaling and LPS exposure can
induce mouse B10pro cells to mature into functional IL-10-
competent B10 cells [27], while LPS or CpG exposure can induce
B10 cells to secrete IL-10. Thus, B10pro and B10 cells provide a
fundamental linkage between the adaptive and innate immune
systems. B10 cells in CD154
TGCD22
2/2 mice were phenotypi-
cally and functionally similar to B10 cells in WT mice, including
their characteristic high levels of CD19 expression and ability to
respond to LPS and CD40 signals (Figure 3; [37]). The current
studies clearly demonstrate that enhanced B cell CD40 signaling in
vivo leads to a remarkable phenotypic outcome characterized by
B10 and B10pro cell expansion, with suppressed isotype switching
and IgG autoAb production that may be attributable to the
regulatory activity of these cells through their production of IL-10.
Depleting the relatively small number of endogenous B10 cells
in wild type mice significantly enhanced isotype switching and IgG
production in response to immunization in the absence of adjuvant
(Figure 5C–D). B10 cell depletion by CD22 mAb also enhances
cellular immunity during EAE initiation [31]. By contrast,
expanded B10 cell numbers in CD154
TGCD22
2/2 mice paral-
leled their IgG-deficient phenotype. Further supporting a
mechanistic explanation for reduced IgG production in
Figure 2. Impaired IgG and GC responses in CD154
TGCD22
2/2 mice. (A) Serum IgM and IgG levels of 4 and 12 mo-old WT, CD22
2/2,
CD154
TG, and CD154
TGCD22
2/2 mice. Symbols represent serum concentrations for individual mice as determined by ELISA, with means indicated by
horizontal bars. (B) Serum autoAbs reactive with dsDNA, ssDNA, or histone proteins in 12 mo-old mice. ELISA OD values for IgM (upper panels) and
IgG (lower panels) autoAbs are shown for individual mice, with means indicated by horizontal bars. Sera from 2 mo-old WT C57BL/6 and 6 mo-old
MLRlpr mice were used as negative and positive controls, respectively. (C) Impaired IgG responses to a TD Ag. WT (n=3), CD22
2/2 (n=4), CD154
TG
(n=6), and CD154
TGCD22
2/2 (n=8) mice were immunized with DNP-KLH in adjuvant on day 0, and boosted on day 21. The graph shows mean
(6SEM) DNP-specific IgG levels as determined by ELISA. Images on the right represent immunofluorescence staining of frozen spleen sections from
all genotypes harvested 7 days after the boost phase of DNP-KLH immunization. Merged images show the presence of B220
+ B cells (red) and GC
GL7
+B220
+ B cells (yellow). Enlarged regions from these sections indicate typical GC structures present within the follicles of WT and CD22
2/2 mice,
and detectable GL7
+B220
+ B cells within the follicles of CD154
TG mice, but not in CD154
TGCD22
2/2 mice (representative regions are shown for
comparison). (A–C) Means significantly different from WT are indicated by asterisks (*p#0.05, **p#0.01), and between other indicated groups by
crosses ({p,0.05, {{p,0.01). (D) Reduced GC B cells in CD154
TGCD22
2/2 mice as quantified by flow cytometry analysis. Mice were immunized with
NP-CGG in alum, with spleens analyzed for GL7
+B220
+ B cells on day 10. Contour plots show mean (6SEM) GL7
+ cell frequencies among total B220
+
cells from n=3 mice of each genotype. Bar graphs show mean (6SEM) GL7
+ B cell numbers from naive (open bars) and immunized (filled bars) mice.
In the contour plots, mean B10 cell frequencies significantly lower than those of WT mice are indicated by asterisks (**p#0.01). In the bar graphs,
means significantly different between naı ¨ve and immunized mice of the same genotype are indicated by asterisks (*p#0.05); crosses for
CD154
TGCD22
2/2 mice indicate that mean GL7
+ cell numbers were significantly reduced relative to all other genotypes ({{p,0.01).
doi:10.1371/journal.pone.0022464.g002
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TGCD22
2/2 mice, B10 cells from CD154
TGCD22
2/2
mice retained their regulatory function and suppressed EAE
during adoptive transfer experiments (Figure 4C). It was not
possible to directly compare the functional activities of B10 cells
from WT and CD154
TGCD22
2/2 mice in vivo because of their
different relative frequencies within the CD1d
hiCD5
+ B cell
subsets used for adoptive transfer experiments (Figure 4A), the fact
that it is not possible to quantify Ag-specific B10 cell frequencies,
and that B10 cells in CD154
TGCD22
2/2 mice are not amenable
to CD22 mAb-induced depletion. Nonetheless, the regulatory
activities of CD1d
hiCD5
+ B cells from CD154
TGCD22
2/2 mice
were strikingly similar to those published for CD1d
hiCD5
+ B cells
from WT mice [31], and B10 cells from CD154
TGCD22
2/2 and
WT mice produced similar levels of cytoplasmic IL-10 following ex
vivo stimulation. Globally impaired IgG responses were also unique
to CD154
TGCD22
2/2 mice, arguing against constitutive CD40
Figure 3. Spleen B10 and B10pro cells expand dramatically in CD154
TGCD22
2/2 mice. (A) Blood, spleen, inguinal LN, and peritoneal cavity
B10 cell numbers in WT, CD22
2/2, CD154
TG, and CD154
TGCD22
2/2 mice. Leukocytes from the indicated tissues were cultured with LPS, PMA, and
ionomycin for 5 h to induce IL-10 production, with monensin included in the cultures to block IL-10 secretion (L+PIM stimulation). The cells were then
stained for cell surface CD19 and cytoplasmic IL-10 with flow cytometry analysis. Monensin treated cells served as negative controls for IL-10
expression. Representative contour plots gated on CD19
+ cells are shown with the percentage of IL-10
+ cells indicated. Bar graphs represent mean
(6SEM) B10 cell frequencies (%) and numbers (#) from $3 mice of each genotype. (B) Similar B10 cell surface phenotypes among mouse genotypes.
Splenocytes were cultured with L+PIM for 5 h and then stained for cell surface molecules and cytoplasmic IL-10. Histograms indicate cell surface
molecule expression by IL-10
+ (thick lines) and IL-10
2 (thin lines) B cells. Dashed histograms represent isotype-matched control mAb staining. Results
are representative of $3 mice of each genotype analyzed. (C) Spleen B10+B10pro cell frequencies and numbers. Splenocytes were cultured with an
agonistic CD40 mAb, with L+PIM added during the final 5 h of 48 h cultures. Cytoplasmic IL-10
+ B cells were identified as in (A). Bar graphs show
means (6SEM) from $3 mice of each genotype. (A,C) Significant differences from WT mice are indicated: *p,0.05, **p,0.01. Means significantly
different between CD154
TGCD22
2/2 and CD154
TG mice are indicated: {p,0.05, {{p,0.01.
doi:10.1371/journal.pone.0022464.g003
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CD154
TG mice (Figure 1A,F), as the explanation for this
observation. It is also unlikely that B10 cells inhibited B cell
differentiation directly since serum IgM levels were elevated in
CD154
TGCD22
2/2 mice. Thus, B10 cell depletion in WT mice
and expansion in CD154
TGCD22
2/2 mice had the predicted
biologic effects of facilitating and inhibiting, respectively, IgG
immune responses.
Agonistic CD40 mAb treatment in vivo ‘‘short-circuits’’ humoral
immunity and impairs IgG production, GC formation, and B cell
memory [13]. Tsubata and colleagues have also found accelerated
termination of GC reactions to T cell-dependent Ags in
Figure 4. CD154
TGCD22
2/2 B10 cells are regulatory. (A) B10 cells in CD154
TGCD22
2/2 mice are found predominately within the spleen
CD1d
hiCD5
+ B cell population. Splenocytes from WT and CD154
TGCD22
2/2 mice were cultured for 5 h with L+PIM to induce IL-10 expression, with
the cells analyzed for cell surface CD19, CD1d and CD5, and intracellular IL-10 expression. CD19
+IL-10
+ and CD19
+IL-10
2 B cells (left panels, gated
regions) were further gated to show relative CD1d and CD5 expression (merged dot plots, right panels). Bar graphs show the mean (6SEM) B10 cell
frequencies within the indicated populations for $4 mice of each genotype based on the gated regions indicated in the merged dot plots. Mean B10
cell frequencies significantly different between cell populations from the same genotype are indicated by asterisks (**p#0.01), and for the same
population between genotypes by crosses ({{p,0.01). (B) Analysis of CD154
TGCD22
2/2 spleen B cell purity within the CD1d
hiCD5
+ (B10-rich) and
CD1d
loCD5
2 populations following cell sorting of splenocytes stained for CD19, CD1d and CD5. These cells were subsequently used for the adoptive
transfer experiments described in (C). (C) B10 cells from CD154
TGCD22
2/2 mice reduce EAE disease severity. Purified CD1d
hiCD5
+ or CD1d
loCD5
2
spleen B cells from naı ¨ve CD154
TGCD22
2/2 mice (B) were either adoptively transferred into WT recipient mice immediately (non-activated) or were
cultured with agonistic CD40 mAb for 48 h with LPS added during the final 5 h of culture before transfer. Other recipient mice received PBS alone
(Control). One day after cell transfers, EAE was induced by MOG immunization. Values represent mean (6SEM) clinical EAE scores from 5 mice per
group, with significant differences from PBS control mice indicated: *p,0.05.
doi:10.1371/journal.pone.0022464.g004
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TG mice, although IgG production remained
robust [14,15]. CD40 agonists also induce extrafollicular B cell
differentiation. The ‘‘short circuiting’’ of IgG responses described
above under robust CD40 ligation conditions (e.g., agonistic CD40
mAb) may be explained in part by the expansion and/or
maturation of B10 and B10pro cells, as occurred in
CD154
TGCD22
2/2 mice. Consistent with this, B10 cells prolif-
erate more rapidly than non-B10 cells following mitogen
stimulation [27]. Therefore, the rapid expansion of Ag-specific
B10 cells within extrafollicular foci of CD154
TGCD22
2/2 mice
may result in Ag consumption and/or clearance by IgM before the
initiation of germinal center reactions and IgG production.
Alternatively, B10 cells may indirectly regulate germinal center
formation by altering TD immunity or the ability of dendritic cells
to act as Ag-presenting cells during T cell activation [31], which
are required for efficient B cell isotype switching.
Treatment of WT mice with the MB22-10 mAb that blocks
CD22 ligand binding preferentially depleted spleen B10 and
CD1d
hiCD5
+ B cells, but not follicular B cells (Figure 5A,B) as
described [31]. While CD22 ligand binding is needed for the
optimal survival of some B cell populations, such as MZ B cells
[34,35,50], B10 cell development was normal in CD22
2/2 mice
and dramatically expanded in CD154
TGCD22
2/2 mice. As such,
CD22 ligation with this particular mAb may induce signals that
promote B10 cell apoptosis, alter their maturation, and/or affect
their tissue distribution. B10 cell localization may be critical for
function since spleen CD1d
hiB220
+ B cells were identified in both
the MZ and follicular regions (Figure 1D), suggesting that B10 cells
Figure 5. Endogenous B10 cells regulate IgG isotype switching in normal mice. (A–B) CD22 mAb treatment preferentially depletes
CD1d
hiCD5
+ and B10 cells. Seven days after WT mice were given CD22 or control mAb, splenocytes were isolated and cultured in the presence of
L+PIM for 5 h followed by cell surface CD19, CD1d and CD5, and intracellular IL-10 staining, with flow cytometry analysis. IL-10
2/2 mice given control
mAb were also evaluated for comparison. (A) CD22 mAb treatment preferentially depletes CD1d
hiCD5
+ B cells. Representative CD1d
hiCD5
+ B cell
frequencies are indicated. (B) CD22 mAb treatment preferentially depletes B10 cells. Representative cytoplasmic IL-10
+ B cell frequencies among
spleen CD19
+ cells are indicated. Bar graphs show mean (6SEM) frequencies and numbers of CD1d
hiCD5
+ B cells (A) or IL-10
+ B10 cells (B) from
control (open bars) and CD22 mAb treated (closed bars) mice. (C–D) B10 cells regulate IgG Ab responses. WT mice were given CD22 or control mAb
(n=3 per group) on day 0, and immunized with DNP-KLH without adjuvant on days 0 and 21. (C) Serum DNP-specific Abs were quantified by ELISA.
(D) The frequency of B cells secreting DNP-specific IgG was determined by ELISPOT analysis of spleen cells harvested on day 28. (A–D) Significant
differences between control and CD22 mAb-treated mice ($3 mice for each treatment group) are indicated: *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0022464.g005
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undetectable in CD22
2/2 mice, yet these mice had significant
numbers of B10 and CD1d
hiB220
+ B cells scattered throughout
their follicles. Intrafollicular CD1d
hi B cells were especially
prominent in CD154
TGCD22
2/2 mice (Figure 1D). In any case,
B cell depletion by the MB22-10 mAb is not dependent on Ab-
dependent cellular cytotoxicity or complement activation [34]. In
addition, the MB22-10 mAb impairs malignant B cell survival in
mice [34]. Therefore, therapeutic B10 cell depletion may be useful
for enhancing IgG responses, or for the treatment of tumors and
immunosuppression.
Foxp3
+CD25
+ Treg cell numbers were normal in both
CD154
TG and CD154
TGCD22
2/2 mice (Table 1). Similarly,
B10 cells do not appear to directly regulate Treg cell numbers in
an EAE model, where these two regulatory subsets function
independently [31]. This suggests that the potential suppressive
effect of B10 cells on IgG production did not result from Treg cell
expansion. By contrast, the adoptive transfer of CD1d
hiCD5
+ B
cells from wild type mice into CD19-deficient NZB/W F1 mice
leads to a significant increase in Treg numbers [46]. While these
results suggest that B10 cells could drive Treg cell expansion, the
majority of spleen CD1d
hiCD5
+ B cells are not B10pro or B10
cells [27]. Thus, the adoptive transfer of non-B10 cells may
independently promote CD4
+ Treg cell generation. This possible
explanation may also apply to studies suggesting that Breg cell-
induced inhibition of inflammation is partly driven by Breg cell-
induced Treg cell expansion. Nonetheless, spleen IL-10-competent
T cell numbers were significantly increased in both CD154
TG and
CD154
TGCD22
2/2 mice relative to WT and CD22
2/2 mice, in
parallel with increased CD4
+ and CD8
+ memory T cell numbers
(Table 1). The increase in IL-10-competent and memory T cells
may therefore result from B cell CD154 expression. It is unlikely
that the increase in IL-10-competent and memory T cells drives
B10 cell expansion since B10 cell expansion was limited to
CD154
TGCD22
2/2 mice. Thus, B cell expression of CD154
appears to have intrinsic effects on B cells as well as extrinsic effects
on cellular immunity.
T and B cell CD154 expression in SLE patients is proposed to
drive autoimmunity [16,17,18], and a clear role for aberrant
CD40 signaling in other inflammatory autoimmune diseases has
emerged in recent years [51,52]. It has also been suggested that
chronic CD40 signaling, particularly in patients with SLE,
functionally inactivates a subset of regulatory B cells [53].
However, the current studies suggest that B cell CD154 expression
may predispose lupus patients towards enhanced B10 cell
production. Consistent with this, B10pro cell numbers are
expanded in SLE patients, and can be induced to mature and
acquire IL-10 competence following agonistic CD40 stimulation
[28]. Therefore, constitutive, robust CD40 signals may drive
functional B10pro cell expansion and limit the pathogenic
consequences of autoimmunity by reducing Ab isotype switching.
Moreover, this study predicts that certain combinations of genetic
traits that can individually induce autoimmune disease may
actually reduce autoimmunity by expanding B10 cell numbers.
For example, CD22
2/2 mice produce high-affinity serum IgG
autoAbs spontaneously with age [54], and hemizygous CD154
TG
mice can develop relatively mild autoimmunity [19,20]. B10 cell
numbers are also expanded in type 1 diabetes-prone NOD mice,
and in lupus-prone MRLlpr and NZB/W F1 mice, even prior to
the appearance of disease [27,38]. Similarly, blood B10pro cell
numbers are expanded significantly in humans with lupus and
other autoimmune diseases [28]. The observation that manipula-
tion of the CD40 and CD22 signaling pathways can drive resident
B10 cell expansion in vivo also highlights a potential therapeutic
benefit for expanding B10 cells in humans to limit the pathogenic
consequences of humoral IgG responses to self Ags.
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